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ABSTRACT
Background Gallstone disease (cholelithiasis) is common. 
In most people it is asymptomatic and does not require 
treatment, but in about 20% it can become symptomatic, 
causing pain and other complications requiring medical 
attention and/or surgery. A proportion of symptomatic 
people with uncomplicated gallstone disease do not 
experience further episodes of pain and, therefore, could 
be treated conservatively. Moreover, surgery carries risks 
of perioperative and postoperative complications.
Methods and analysis C- Gall is a pragmatic, multicentre, 
randomised controlled trial and economic evaluation 
to assess whether cholecystectomy is cost- effective 
compared with observation/ conservative management 
(here after referred to as medical management) at 18 
months post- randomisation (with internal pilot).
Primary outcome measure Patient- reported quality of 
life (QoL) (36- Item Short Form Survey (SF-36) bodily pain 
domain) up to 18 months after randomisation.
The primary economic outcome is incremental cost per 
quality- adjusted life year gained at 18 months.
Secondary outcome measures Secondary outcome 
measures include condition- specific QoL, SF-36 domains, 
complications, further treatment, persistent symptoms, 
healthcare resource use, and costs assessed at 18 and 
24 months after randomisation. The bodily pain domain 
of the SF-36 will also be assessed at 24 months after 
randomisation.
A sample size of 430 participants was calculated. 
Computer- generated 1:1 randomisation was used.
The C- Gall Study is currently in follow- up in 20 UK research 
centres. The first patient was randomised on 1 August 2016, 
with follow- up to be completed by 30 November 2021.
Statistical analysis Statistical analysis of the primary 
outcome will be intention- to- treat and a per- protocol 
analysis. The primary outcome, area under the curve 
(AUC) for the SF-36 bodily pain up to 18 months, will be 
generated using the Trapezium rule and analysed using 
linear regression with adjustment for the minimisation 
variables (recruitment site, sex and age). For the secondary 
outcome, SF-36 bodily pain, AUC up to 24 months will 
be analysed in a similar way. Other secondary outcomes 
will be analysed using generalised linear models with 
adjustment for minimisation and baseline variables, as 
appropriate. Statistical significance will be at the two- 
sided 5% level with corresponding CIs.
Ethics and dissemination The North of Scotland 
Research Ethics Committee approved this study (16/
NS/0053). The dissemination plans include Health 
Strengths and limitations of this study
 ► First multicentre randomised controlled trial com-
paring surgical treatment with medical management 
in symptomatic uncomplicated gallstone disease.
 ► C- Gall group included patients and researchers with 
a wide range of experience in gallstone disease, 
ensuring that the study is robust for all relevant 
stakeholders.
 ► Adherence to accepted international methodological 
standards, ensuring that high- quality recommenda-
tions are produced.
 ► Lifelong follow- up of the recruited patients is not 
currently proposed.  on M
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Technology Assessment monograph, international scientific meetings and 
publications in high- impact, open- access journals.
Trial registration number ISRCTN55215960; pre- results.
INTRODUCTION
Gallstone disease (cholelithiasis) is one of the most 
common gastrointestinal disorders in industrialised 
societies. The prevalence of gallstones in adult popu-
lations is approximately 10%–15%.1–4 Gallstones are 
more common in women and people over the age of 
40 years.5 In most people, gallstones are asymptomatic. 
About 20% of people with gallstones experience pain and 
complications.6
Clinical surveys conducted in Europe, North and South 
America, and Asia indicate that prevalence rates for gall-
stone disease range from 5.9% to 25%7–10 and tend to 
increase with age. A clinical ultrasound survey conducted 
in the UK reported prevalence rates of 12% among men 
and 22% among women over 60 years of age.9 A multi-
centre population- based study conducted in Italy has 
reported an annual incidence of gallstone disease of 
0.66% in men and 0.81% in women.11
The natural course of gallstone disease is benign, with 
relatively low progression from asymptomatic disease to 
symptomatic disease.6 Natural history studies have shown 
low mortality from gallstone disease with typically less than 
1% of people dying from gallbladder- related causes.6 12 13 
In a population- based study published in 2010, the overall 
frequency of symptom development in asymptomatic 
people was around 20% over a long follow- up period 
(mean 8.7 years).6
In people with symptomatic uncomplicated gallstone 
disease, the annual rates of developing complications 
have been reported to be as low as 1%–3%.14–16 The 
Italian Group for the Epidemiology and Prevention of 
Cholelithiasis Study reported an annual incidence of 
complications of 0.7% for symptomatic people.13
In the UK and North America, the number of surgical 
procedures for gallstone disease increased steadily 
between the 1950s and 1990s, reflecting both the rise 
in prevalence of identified gallstone disease and the use 
of cholecystectomy as the treatment of choice. Rates of 
surgical procedures stabilised in both countries towards 
the end of the 20th century.
Impact of health problem
From a patient perspective, the defining symptom of gall-
stone disease is pain.17 18 Commonly, general abdominal 
symptoms intensify over a period of time and become 
regular pain attacks (biliary colic) and may require 
medical attention. Best medical therapy includes the 
prescription of analgesics and, when necessary, anti- 
inflammatory drugs or antibiotics.
The most common complications associated with gall-
stones are severe acute cholecystitis, which may lead to 
complications such as empyema, obstructive jaundice due 
to the obstruction of the common bile duct, acute cholan-
gitis and acute pancreatitis.
A recent large prospective study conducted in the 
UK (8909 participants) has shown that 10.8% of people 
experienced complications 30 days after surgery.19 Even 
though removal of the gallbladder is considered the 
standard treatment for symptomatic gallstones, it does 
not guarantee eradication of symptoms.20 A proportion 
of people (up to 40% of people) may continue to expe-
rience pain and abdominal symptoms after surgery.21 In 
particular, persistent pain, similar to that experienced 
preoperatively, has been reported in about 20% of people 
after cholecystectomy,22 23 and de novo pain has been 
reported in up to 14% of people.24
The term ‘post- cholecystectomy syndrome’ is an 
umbrella term which has been widely used to describe the 
range of symptoms which occur after cholecystectomy.25 
The term ‘persistent post- cholecystectomy symptoms’ has 
been suggested as a more accurate description of these 
symptoms.26 Symptoms include biliary and non- biliary 
abdominal pain, gastrointestinal disorders, dyspepsia, 
heartburn, nausea, vomiting, jaundice and cholangitis. 
Persistent diarrhoea or constipation is often reported 
after cholecystectomy and flatulence may arise de novo 
after surgery.24 In some people, functional gastrointes-
tinal disorders and not gallstone disease may be the cause 
of persistent post- surgery symptoms.27 Nevertheless, there 
is not a consistent pathophysiological explanation for 
persistent post- cholecystectomy symptoms and, in about 
5% of people, the reason for persistent abdominal pain 
remains unknown.28
Rationale for the trial
Current clinical guidelines recommend laparoscopic 
cholecystectomy for patients with biliary pain or acute 
cholecystitis and radiological evidence of gallstones.29 
Cholecystectomy is, therefore, the default option for 
people with symptomatic gallstone disease and one 
of the most common and costly surgical procedures 
performed in the National Health Service (NHS) in the 
UK. Some 74 373 cholecystectomies were performed 
in England in 2019 (61 584 following elective admis-
sions).30 These figures indicate that although some 
patients are operated in the acute hospital setting, 
many patients with uncomplicated symptomatic gall-
stone disease are put on a waiting list and operated on 
electively.
However, medical management may be a valid thera-
peutic option in people presenting with uncomplicated 
disease depending on their age, clinical presenta-
tion and evolution of symptoms over time. Moreover, 
as these symptoms are usually not urgent, it may be 
reasonable to take into consideration a non- surgical 
option first, which could save a considerable amount of 
NHS resources.
Recent studies stated that half of the people treated 
medically were symptom free; therefore, up to 30 000 
cholecystectomies per year could potentially be avoided 
with a likely saving for the NHS of £68 million/year. 
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These resources could be freed (disinvestment) and 
allocated to fund alternative healthcare within the NHS.
Early natural history studies and more recent obser-
vational and population- based studies have suggested 
that a proportion of people with symptomatic gallstone 
disease no longer experience biliary pain after the 
onset of symptoms.6 12 13 21 31 Larsen and Qvist21 found 
that 45% of symptomatic people on watchful waiting 
were totally relieved from symptoms during a 1- year 
observation period. Similarly, Festi et al observed that 
58% of people with initially mild symptoms and 52% of 
those with more severe symptoms did not experience 
further episodes of pain during a follow- up period of 
10 years and the severity of the disease did not increase 
over time.6
A recent National Institute for Health Research 
(NIHR) Health Technology Assessment (HTA) found 
that on average cholecystectomy is more costly but 
more effective than medical management for the 
treatment of symptomatic gallstones or cholecystitis.32 
Nevertheless, half of the people treated medically were 
symptom free and did not require surgery in the long 
term, indicating that there is probably a proportion 
of patients with uncomplicated symptoms who could 
benefit from medical management. The specific results 
were that participants randomised to observation 
were significantly more likely to experience gallstone- 
related complications (risk ratio (RR) 6.69; 95% CI 
1.57 to 28.51; p=0.01), in particular acute cholecys-
titis (RR 9.55; 95% CI 1.25 to 73.27; p=0.03); but less 
likely to undergo surgery (RR 0.50; 95% CI 0.34 to 0.73; 
p=0.0004) and experience surgery- related complica-
tions (RR 0.36; 95% CI 0.16 to 0.81; p=0.01) than those 
randomised to surgery. Fifty- five per cent of people 
randomised to observation did not require an opera-
tion during the 14- year follow- up period, and 12% of 
people randomised to cholecystectomy did not undergo 
the scheduled operation. These results were subject to 
major uncertainties in the reported economic model. 
Even when cholecystectomy occurred, medical manage-
ment had between 40% and 60% chance of being cost- 
effective for alternative values of willingness to pay for 
an additional quality- adjusted life year (QALY).
Furthermore, results were strongly influenced by 
the proportion of individuals originally followed with 
medical management that needed surgery. In their 
base case, the authors assumed that 44% of the cohort 
would need surgery within 5 years. If this proportion 
was reduced to 25%, medical management became, 
on average, cost- effective. It is worth pointing out 
that the NIHR HTA was based on evidence from two 
randomised controlled trials (201 participants in 
total)33 34 conducted in Norway by the same research 
team. Due to the limited evidence available and the 
current lack of UK NHS data, the authors highlighted 
the need for a large, well- designed trial assessing the 




The primary aim of the study is to assess the clinical and 
cost- effectiveness of observation/conservative manage-
ment (here after referred to as medical management) 
compared with cholecystectomy for preventing recur-
rent symptoms and complications in adults presenting 
with uncomplicated symptomatic gallstones in a 
secondary care setting.
The primary patient objective is to compare medical 
management with cholecystectomy in terms of partic-
ipants’ quality of life using the 36- Item Short Form 
Survey (SF-36) bodily pain domain at up to 18 months 
after randomisation.
The primary economic objective is to assess the cost- 
effectiveness of medical management versus cholecys-
tectomy in terms of the incremental cost per QALY.
The secondary objectives are to compare medical 
management with surgical treatment (cholecystec-
tomy) in terms of condition- specific quality of life, 
SF-36 domains, complications, the need for further 
treatment, persistent symptoms, healthcare resource 
use and costs. All secondary outcomes are assessed at 18 
and 24 months after randomisation.
The bodily pain domain of the SF-36 health survey 
will also be assessed at 24 months after randomisation 
as a secondary objective.
Blinding of outcomes is not possible.
The null hypothesis being tested is that there is no 
difference between medical management and cholecys-
tectomy. The alternative hypothesis is that cholecystec-
tomy is superior.
Trial design
A pragmatic, phase 4, multicentre parallel group 
patient randomised superiority trial (with an internal 
pilot phase) to test if the strategy of standard cholecys-
tectomy is more (cost- )effective than medical manage-
ment (with internal pilot). Other than the collection of 
outcome data, participant care will follow standard care 
pathways in the participating NHS secondary care sites. 
A within- trial economic evaluation will be conducted. 
Linear regression models will be used for this. Extrapo-
lation beyond the trial follow- up period will be consid-
ered if a definite answer on cost- effectiveness cannot be 
reached from the within- trial analysis.
The patient- reported outcomes (SF-36; Condi-
tion Specific Questionnaire/CSQ) will be assessed by 
participant- completed questionnaires at baseline, 3, 
9, 12 and 18 months and 6 monthly thereafter, post- 
randomisation, until the end of the trial. A case report 
form (CRF) will be completed at the time of surgery, 
providing details of the operative procedures, compli-
cations and resource use in the hospital. Costs of the 
initial intervention procedures will be estimated from 
resource use data recorded on the CRFs coupled with 
routine unit cost data. Costs associated with subsequent 
contacts with primary and secondary care (eg, due 
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to symptomatic gallstones or surgical complications) 
will be estimated from patient questionnaires at 3, 
9, 12 and 18 months and 6 monthly thereafter, post- 
randomisation, until the end of the trial and checked 
at the source. QALYs will be estimated from patients’ 
responses to the SF-36. The trial flow chart is shown in 
figure 1.
Embedded qualitative research will identify any 
challenges during the internal pilot related to design 
or conduct that can then be addressed and modified 
during progression to the full trial. Full details are given 
in trial protocol.
Interventions to be evaluated
1. Cholecystectomy. Laparoscopic cholecystectomy is the 
current standard surgical procedure for the manage-
ment of symptomatic gallstone disease. The gall blad-
der is removed with the stones within it using keyhole 
techniques (laparoscopy). The procedure is under-
taken under a general anaesthetic. It usually involves 
three to four small incisions in the abdomen, which 
allow the surgeon to dissect the gallbladder from its 
attachments and safely divide the key anatomical struc-
tures (the cystic duct and artery) that link it to the 
biliary tree. The gallbladder is separated from under 
Figure 1 Trial flow chart. CRF, case report form; CSQ, Condition Specific Questionnaire; SF-36, 36- Item Short Form Survey.
 on M
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the surface of the liver. Usually, the gallbladder (con-
taining the stones) is removed within a retrieval bag 
via one of the small incisions. The operation takes be-
tween 45 and 120 min, many patients are admitted for 
one night, although day case laparoscopic cholecystec-
tomy is safely undertaken in otherwise fit patients with 
appropriate social support.
2. Medical management. This includes the prescription 
of analgesics and antispasmodics to relieve the bili-
ary pain. Typical therapy includes paracetamol, non- 
steroidal anti- inflammatory drugs (eg, ibuprofen), 
narcotic analgesics (eg, opiates), antispasmodics (eg, 
Buscopan), together with generic lifestyle advice.35 36 In 
the longer term, medical management also may involve 
these strategies for symptom management, if required, 
as well as advice to eat a healthy diet with regular meals 
(http://www. nhs. uk/ Conditions/ Gallstones/ Pages/ 
Treatment. aspx). For the purpose of this trial, a stan-
dard protocol for medical management was agreed 
with the Patient and Public Involvement group and 
used in all participating centres. Safety advice for pa-
tients in the medical management group was aligned 
with the current advice given via the NHS choices web-
site ( www. nhs. uk).
Trial population
Adults with symptomatic uncomplicated gallstone disease 
(biliary pain) who are electively referred to a secondary 
care setting and considered suitable for cholecystectomy.
A sample size of 430 participants was calculated.
Setting
Adult patients with diagnosed symptomatic uncompli-
cated gallstone disease electively referred to a secondary 
care setting by a general practitioner (GP), accident 
and emergency department or elsewhere, not requiring 
emergency surgical or endoscopic intervention will be 
approached by the research teams.
Planned inclusion and exclusion criteria
Inclusion criteria
All adult patients with confirmed symptomatic gallstone 
disease electively referred to a secondary care setting for 
consultation.
Clinical diagnosis of gallstone disease will be confirmed 
by imaging. Transabdominal ultrasonography is the 
standard imaging technique for the diagnosis of gall-
bladder stones, but diagnosis by any imaging technique 
is acceptable.
Exclusion criteria
 ► Unable to consent.
 ► Medically unfit for surgery.
 ► Current pregnancy.
 ► Previous open major upper abdominal surgery.
 ► Gallstones in common bile duct or evidence of 
previous choledocholithiasis (gallstones in common 
bile duct) on latest imaging or evidence of previous 
choledocholithiasis.
 ► A history of acute pancreatitis.
 ► Evidence of empyema of the gallbladder with sepsis.
 ► Suspicion of gallbladder cancer.
 ► Perforated gallbladder (refers to recent or old perfo-
ration detected on imaging).
 ► Haemolytic disease.
 ► Gallstone ileus.
Recruitment and trial procedures
Identifying participants
GPs within the study area have an important role in 
raising awareness among those potential recruits to the 
study that they are referring or admitting to hospital. We 
will provide information about the study to all referring 
GPs within the study areas. In Scotland, we will contact 
and attend the relevant health boards’ GP subcommit-
tees. Subsequently, we will work with the boards’ primary 
care directorate to cascade information to individual 
GP practices and registered locums. In England, we will 
contact the relevant Clinical Research Network primary 
care leads and seek permission to contact referring GPs 
within their grouping.
Additionally, in the regions where the study is taking 
place, we will liaise with the relevant clinical commissioning 
groups as a further means of cascading information to 
relevant GPs. We will provide GPs with standardised infor-
mation about the study and make the protocol available 
to them. We will encourage GPs to make patients aware of 
the study and why it is being conducted when they refer 
or admit potential recruits to the study. Participants will 
be identified by the local research team at participating 
centres. Local procedures at the participating hospitals 
are different, and the timing and mode of approach to 
patients and the consent process may vary to accommo-
date both the specific circumstances at each site and the 
needs of the patients.
Following identification of potential participants, an 
invitation letter and patient information leaflet (PIL) 
detailing the trial will be sent out, inviting them to attend 
an outpatient clinic where the trial and their treatment 
will be discussed. Potential participants, not identified 
prior to a clinic visit or at sites that are unable to send 
the PIL in advance, will be given the PIL at the outpa-
tient clinic. The PIL will also highlight that the clin-
ical consultation may be audio- recorded if participants 
consent. At the clinic consultation, the research team will 
outline the trial and ask the patient if they are willing to 
discuss participation and have their conversation audio- 
recorded. For those patients who are happy with this 
proposal, the process will follow as described. A member 
of the local research team will complete a trial screening 
form using information from the prospective participant 
and from the clinical record to document fulfilment of 
the entry criteria. Eligibility criteria will be cross- checked 
with the clinical record. If the patient is eligible and in 
provisional agreement, a local research team member will 
meet with the patient immediately in the clinic. Eligible 
participants who express interest in participating will 
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have the study explained to them by local research staff 
and asked if they have any questions or concerns about 
participating in the trial. If they agree to take part, they 
will give written consent to be randomised. Standard local 
arrangements concerning pre- assessment, admission, 
consent for surgery, conduct of surgery and aftercare will 
continue unimpaired.
The PIL and consent form refer to the possibility of 
long- term follow- up to determine the incidence of future 
operations. The PIL and consent form also refer to the 
possibility of participants being contacted in the future 
to participate in other relevant research. Eligible and 
randomised participants, as well as those who are not 
willing to consider randomisation, may be contacted to 
participate in a semistructured audio- recorded interview.
The PIL provides clear details of the anticipated risks 
and benefits of trial participation. Risks associated with 
both treatment arms are explicitly mentioned. The risk 
and benefits of the study will also be discussed by the local 
research nurses and the patient’s consultant as part of the 
process of obtaining informed consent.
Informed consent
Informed consent to participate in the trial will be 
sought and obtained according to Good Clinical Prac-
tice (GCP) guidelines. Informed signed consent forms 
will be obtained from the participants in all centres by 
an appropriately trained individual. Participants will be 
given sufficient time to accept or decline involvement and 
will be free to come out of the study at any time. Patients 
may decide to participate during an initial consultation, 
during a subsequent visit to the hospital or alternatively at 
home. If the patient agrees to be contacted at home, he/
she may receive a telephone call from the local research 
nurse to discuss any queries. Patients who decide to 
participate following telephone counselling can either 
send their completed documents (consent form and base-
line questionnaire) through the post to the local team at 
their treating hospital or bring it with them if they are 
returning to the hospital for another consultation.
An embedded evaluation using qualitative research 
methods will underpin recruitment development and 
inform how best to interpret the results of the trial. The 
qualitative component is entirely optional, but consent will 
be sought to audio- record the initial consultation when 
the trial is discussed (to explore opportunities to improve 
the informed consent discussion) and for interviews with 
both those who consent and refuse randomisation (to 
identify opportunities to improve trial processes).37
Participants who cannot give informed consent (eg, 
due to their mental state) are not eligible for either the 
randomised trial or the qualitative work.
Randomisation and allocation
Eligible and consenting participants will be randomised 
to one of the two intervention groups using the 24- hour 
telephone Interactive Voice Response randomisation 
application or via the web- based application, both hosted 
by the Centre for Healthcare Randomised Trials. The 
randomisation algorithm will use recruitment site, sex 
(male/female) and age (<35, 35–64, ≥65 years) as mini-
misation covariates to allocate treatment to intervention 
and control groups in a 1:1 ratio. A random element 
will be incorporated into the randomisation algorithm. 
The principal investigator (PI) at each site, or individual 
with delegated authority, will access the telephone or 
web- based system. Patient screening identification infor-
mation, including patient initials, sex, date of birth and 
recruiting site (the stratifying variables), will be entered 
into the voice- activated or web- based system, which will 
return the allocation status. After obtaining patient 
consent, randomisation will happen in the clinic, and 
participants will be informed of their allocated treatment 
group following randomisation. If the participants are 
not present in the clinic, they will be contacted by the 
research teams to inform them of the allocated treatment 
group after randomisation.
Follow-up procedures
The patient reported outcomes (SF-36; CSQ) will be 
assessed by participant- completed questionnaires at 
baseline, 3, 9, 12 and 18 months and 6 monthly there-
after, post- randomisation, until the end of the trial. A 
CRF at the time of any gallstone surgery will be collected 
providing details of the operative procedures, complica-
tions and resource use in the hospital. Costs of the initial 
intervention procedures will be estimated from resource 
use data recorded on the CRFs coupled with routine unit 
cost data. Costs associated with subsequent contacts with 
primary and secondary care (due to symptomatic gall-
stones) will be estimated from patient questionnaires at 
3, 9, 12 and 18 months and 6 monthly thereafter, post- 
randomisation, until the end of the trial and checked 
at the source. QALYs will be estimated from patients’ 
responses to the SF-36.
Change of status/withdrawal procedures
Participants will remain in the trial unless they choose to 
withdraw consent or if they are unable to continue for a 
clinical reason. All changes in status with the exception 
of complete withdrawal of consent will mean the partic-
ipant is still followed up for all trial outcomes, wherever 
possible. All data collected up to the point of complete 
withdrawal will be retained and used in the analysis.
Subsequent arrangements
Informing key people
Following formal trial entry:
The study office will:
1. Inform the participant’s GP (by letter) enclosing in-
formation about C- Gall and the study office contact 
details.
The local research nurse/recruitment officer and/or 
PI will:
1. File the hospital copy of the consent form in the hospi-
tal notes along with information about C- Gall.
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2. Inform the ward and theatre staff as appropriate of the 
participant’s entry to the trial and details of the inter-
vention allocation (theatre only).
3. Use the C- Gall internet database to enter data regard-
ing the participant, including data required to com-
plete randomisation; and intraoperative and postop-
erative information abstracted from local medical re-
cords.
4. Maintain and archive study documentation at the site. 
A copy of the signed consent form is returned to the 
study office in Aberdeen after database entry.
5. Provide any relevant, follow- up clinical data.
Monitoring the participants
Participants will be contacted by phone, post or email 
as appropriate. Participants will be asked to contact the 
study office when they are given an appointment for their 
surgery. In case of non- return of questionnaires or non- 
attendance at outpatient appointments, attempts will be 
made by staff at the study office to trace the participant 
directly using these means or indirectly by contacting the 
GP.
Notification by GPs
GPs are asked to contact the study office if the participant 
moves, becomes too ill to continue or dies, or any other 
notifiable or adverse event occurs. Alternatively, the staff 
at the study office may contact the GP.
Offices for National Statistics (NHS digital data in England, 
Information Statistics Division data in Scotland)
Consent will be sought from all participants to trace their 
medical records and addresses from local records and 
centrally held computerised databases. This should facili-
tate long- term follow- up.
Patient and public involvement
Patients and the public have been key to the develop-
ment of the study, and this is facilitated through a named 
contact within the research team. Two patient partners 
(one as a member of the Project Management Group 
has been involved since the design stage, one as an inde-
pendent member of the Trial Steering Committee with 
an oversight role) have been involved throughout key 
decision points of the trial conduct with opportunities to 
comment on and help inform the improvement of aspects 
of conduct and recruitment. Additional patient perspec-
tives are obtained through a dedicated patient group of 
six people set up through the trial who contribute their 
perspectives on disease and the two interventions being 
studied.
Sample size
The primary outcome is the area under the curve (AUC) 
measure from SF-36 bodily pain up to 18 months. To 
detect a 0.33 SD difference, with 90% power and alpha at 
5%, 194 participants per group (388 in total) are required. 
To allow for 10% of participants for whom outcome data 
will be completely missing, and there the AUC cannot be 
calculated, it is proposed to randomise 430 participants 
in total.
Internal pilot
The internal pilot was primarily designed to verify 
that recruitment was possible. There were three areas 
of uncertainty that we proposed to verify during the 
internal pilot study. These areas were (1) the generalis-
ability of the randomised participants, (2) the willingness 
to randomise and (3) ability to scale up the number of 
centres. To address these areas, we initially set up four 
selected pilot centres in the first 12 months of the study. 
Within these four centres, detailed clinical screening 
logs were implemented. The screening logs recorded 
the number of screened participants, the number inel-
igible and number eligible. The four centres also took 
part in embedded qualitative research to help the trial 
team understand barriers and facilitators to recruitment 
during this phase. From months 12 to 24, the internal 
pilot continued with the scaling up of the trial to the rest 
of the trial centres.
Stop/go criteria
During the internal pilot phase, we proposed two deci-
sion points—one at month 12 and another at month 18. 
By month 12, 14 centre months of recruitment should 
have occurred, and 20 participants randomised across the 
four centres. By end of month 18, 94 centre months of 
recruitment should have occurred, and 111 participants 
randomised across 20 centres. After the internal pilot, 
we also proposed an early check of the AUC assumption, 
average recruitment rate and rate of crossovers during 
follow- up. The proposed stop/go criteria were:
At 12 months:
 ► Recruited projected participants (currently 20).
 ► Recruited at least 20% of eligible patients.
At 18 months:
 ► Recruited the appropriate number of centres to 
achieve recruitment target (currently 20).
 ► The average recruitment rate per site per month is at 
least one.
At 24 months:
 ► The AUC estimate is no more than 10% larger than 
current estimate of 0.33.
 ► The crossover rate is greater than 50%.
STATISTICAL ANALYSIS
The primary outcome, AUC for the SF-36 bodily pain 
up to 18 months, will be generated for each participant 
using the Trapezium rule. The primary outcome (differ-
ence in mean AUC) measure will be analysed using linear 
regression with adjustment for the minimisation vari-
ables (site of recruitment, sex and age). Sensitivity anal-
yses of all treatment effect estimates for participants who 
have missed a scheduled questionnaire will be estimated 
using a multiple imputation approach to make use of 
partial outcome data. We will also assess the robustness 
of the treatment effect estimates to these approaches. 
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Missing items on the health- related outcome measures 
will be treated as per the instructions for that particular 
measure. For the secondary outcome, SF-36 bodily pain 
AUC up to 24 months will be analysed in a similar way to 
the primary outcome. All other secondary outcomes will 
be analysed using generalised linear models with adjust-
ment for minimisation and baseline variables, as appro-
priate. Statistical significance will be at the two- sided 5% 
level with corresponding CIs derived. Subgroup analyses 
will explore the possible modification of treatment effect 
by clinically important factors: sex and age. This will be 
done by including treatment- by- factor interactions in 
the model, and they will be classified as exploratory anal-
yses with 99% CIs calculated. All analyses will initially be 
performed on an intention- to- treat basis, although we will 
consider additional analysis groups such as per- protocol 
(definitions of the per- protocol group will be detailed in 
the Statistical Analysis Plan). The main statistical anal-
yses will be based on all participants as randomised, irre-
spective of subsequent compliance with the treatment 
allocation. From the internal pilot phase, we will report 
estimates of recruitment rates and potential participant 
availability, together with appropriate CIs. There are no 
planned interim outcome analyses; all analyses will occur 
following completion of trial follow- up. Interim analyses 
will be performed if requested by the Data Monitoring 
and Ethics Committee.
ECONOMIC EVALUATION
A within- trial cost- utility analysis will be conducted. The 
need to extrapolate beyond the study follow- up period 
will be considered if a definite answer on cost- effectiveness 
cannot be obtained from within the trial analysis.
Resource use and costs will be estimated for each partic-
ipant. Hospital inpatient and outpatient resource use 
data (eg, hospital admissions by type of service, outpa-
tient visits and so on) will be retrieved from participants’ 
hospital case notes. In addition, primary care resource 
use (eg, GP visits), time off work, out- of- pocket purchases 
of medications and quality of life data (eg, SF-36) will be 
obtained from patient questionnaires at 3, 9, 12, 18 and 24 
months. The analysis will be conducted from the UK NHS 
and personal social services’ perspective, and resource 
use will be valued using standard UK sources.38–40 Based 
on participant responses to the SF-36, utility scores will 
be obtained and used to calculate QALYs for each trial 
participant.41–43
Cost- effectiveness will be measured in terms of costs 
of the care pathways and QALYs at 24 months post- 
randomisation for the within the trial analysis. Mean NHS 
costs, patient costs and QALYs will be compared between 
randomised groups at 24 months. Incremental costs, incre-
mental QALYs and incremental cost- effectiveness ratios 
will be reported. Appropriate linear regression models 
with adjustment for minimisation variables and baseline 
variables (eg, baseline utility scores) will be used. Uncer-
tainty will be characterised and presented graphically 
using cost- effectiveness acceptability curves.33 34 Guide-
lines for economic evaluation advocate for a long enough 
time horizon to consider all cost and consequences rele-
vant to the analysis.44 If extrapolating the results beyond 
the clinical trial follow- up, a simple state transition model 
(eg, Markov model) will be developed.
Ethics approval
The North of Scotland Research Ethics Committee (REC) 
has reviewed and approved this study. The study will be 
conducted according to the principles of GCP provided 
by the research governance guidelines. We believe this 
study does not pose any specific risks to individual partic-
ipants beyond standard surgical procedures, nor does it 
raise any extraordinary ethical issues. Annual progress 
reports and a final report at the conclusion of the trial 
will be submitted to the North of Scotland REC within the 
timelines defined in the regulations.
Finance and insurance
The trial is funded by a grant awarded by the UK NIHR 
HTA Programme. The University of Aberdeen provides 
the necessary trial insurance.
DISCUSSION
In the light of available clinical guidelines, laparoscopic 
cholecystectomy remains the default option for all people 
with symptomatic uncomplicated gallstone disease. At 
present, healthcare professionals have little information 
available to guide them in identifying people who might 
benefit from a conservative approach. Current national 
data from the UK have shown that more than 70 000 
surgical procedures to remove gallbladder are performed 
nationally every year. It is uncertain whether these proce-
dures are warranted, and high- quality evidence to inform 
this debate is needed. The C- Gall trial is designed to 
contribute to this discussion.
Recruitment has completed, and the trial is in its 
follow- up phase. It is expected that results will be avail-
able in 2022.
Dissemination
The dissemination plans include (1) publication in the 
NIHR Journals Library, (2) presentation at international 
scientific meetings and (3) publications in high- impact, 
open- access, peer- reviewed journals.
Trial status
The C- Gall Study has completed recruitment in 20 UK 
research centres and is currently in follow- up in these 20 
UK research centres. The first patient was randomised 
on 1 August 2016, with follow- up to be completed by 30 
November 2021.
Protocol V.11.0, 06 July 2020.
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